ROIV
Roivant Sciences Ltd.
Biotechnology
Market Cap$20.51B
5Y Perf.+178.1%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ROIV vs ABBV vs PFE vs BMY
Revenue, margins, valuation, and 5-year total return — side by side.
ABBV
AbbVie Inc.
Drug Manufacturers - General
Market Cap$358.42B
5Y Perf.+89.1%
PFE
Pfizer Inc.
Drug Manufacturers - General
Market Cap$150.63B
5Y Perf.-28.1%
BMY
Bristol-Myers Squibb Company
Drug Manufacturers - General
Market Cap$114.85B
5Y Perf.-9.3%
ROIV vs ABBV vs PFE vs BMY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ROIV | ABBV | PFE | BMY |
|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - General | Drug Manufacturers - General | Drug Manufacturers - General |
| Market Cap | $20.51B | $358.42B | $150.63B | $114.85B |
| Revenue (TTM) | $13M | $61.16B | $63.31B | $48.48B |
| Net Income (TTM) | $-809M | $4.23B | $7.49B | $7.28B |
| Gross Margin | 91.2% | 70.2% | 69.3% | 68.7% |
| Operating Margin | -91.3% | 26.7% | 23.4% | 25.7% |
| Forward P/E | — | 14.3x | 8.9x | 8.9x |
| Total Debt | $100M | $69.07B | $67.42B | $47.14B |
| Cash & Equiv. | $2.72B | $5.23B | $1.14B | $10.21B |
ROIV vs ABBV vs PFE vs BMY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ROIV
ABBV
PFE
BMY
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Roivant Sciences Lt… (ROIV) | 100 | 278.1 | +178.1% |
| AbbVie Inc. (ABBV) | 100 | 189.1 | +89.1% |
| Pfizer Inc. (PFE) | 100 | 71.9 | -28.1% |
| Bristol-Myers Squib… (BMY) | 100 | 90.7 | -9.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ROIV vs ABBV vs PFE vs BMY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BMY leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. AbbVie Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. ROIV and PFE also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
ROIV
Roivant Sciences Ltd.
The Momentum Pick
ROIV is the clearest fit if your priority is momentum.
- +153.2% vs ABBV's +11.3%
Best for: momentum
ABBV
AbbVie Inc.
The Growth Play
ABBV is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 8.6%, EPS growth -0.8%, 3Y rev CAGR 1.8%
- 295.5% 10Y total return vs ROIV's 171.9%
- 8.6% revenue growth vs ROIV's -11.2%
- Beta 0.34 vs ROIV's 0.95
Best for: growth exposure and long-term compounding
PFE
Pfizer Inc.
The Income Pick
PFE is the clearest fit if your priority is income & stability.
- Dividend streak 15 yrs, beta 0.54, yield 6.5%
- 6.5% yield, 15-year raise streak, vs ABBV's 3.2%, (1 stock pays no dividend)
Best for: income & stability
BMY
Bristol-Myers Squibb Company
The Defensive Pick
BMY carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.50, current ratio 1.26x
- Beta 0.50, yield 4.4%, current ratio 1.26x
- Lower P/E (8.9x vs 8.9x)
- 15.0% margin vs ROIV's -60.8%
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ABBV | 8.6% revenue growth vs ROIV's -11.2% |
| Value | BMY | Lower P/E (8.9x vs 8.9x) |
| Quality / Margins | BMY | 15.0% margin vs ROIV's -60.8% |
| Stability / Safety | ABBV | Beta 0.34 vs ROIV's 0.95 |
| Dividends | PFE | 6.5% yield, 15-year raise streak, vs ABBV's 3.2%, (1 stock pays no dividend) |
| Momentum (1Y) | ROIV | +153.2% vs ABBV's +11.3% |
| Efficiency (ROA) | BMY | 7.9% ROA vs ROIV's -15.5%, ROIC 16.9% vs -50.4% |
ROIV vs ABBV vs PFE vs BMY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
FY 2025
FY 2025
ROIV vs ABBV vs PFE vs BMY — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLROIVLAGGINGBMY
Who Leads Where
ABBV leads in 1 of 6 categories
BMY leads 1 • ROIV leads 1 • PFE leads 1 • 2 tied
Explore the data ↓BMYBristol-Myers Squibb …
1leads
PFEPfizer Inc.
1leads
ABBVAbbVie Inc.
1leads
ROIVRoivant Sciences Ltd.
1leads
6 Total Categories
CATEGORYLEADERvs ABBVvs PFEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ABBV4/6
Valuation MetricsMultiples, price ratios, and targets
BMY4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
ROIV5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
PFE2/2
Income & Cash Flow (Last 12 Months)
ABBV leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PFE is the larger business by revenue, generating $63.3B annually — 4756.9x ROIV's $13M. BMY is the more profitable business, keeping 15.0% of every revenue dollar as net income compared to ROIV's -60.8%. On growth, ABBV holds the edge at +10.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ROIVRoivant Sciences … | ABBVAbbVie Inc. | PFEPfizer Inc. | BMYBristol-Myers Squ… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $13M | $61.2B | $63.3B | $48.5B |
| EBITDAEarnings before interest/tax | -$1.2B | $24.5B | $21.0B | $15.7B |
| Net IncomeAfter-tax profit | -$809M | $4.2B | $7.5B | $7.3B |
| Free Cash FlowCash after capex | -$767M | $18.7B | $9.5B | $11.9B |
| Gross MarginGross profit ÷ Revenue | +91.2% | +70.2% | +69.3% | +68.7% |
| Operating MarginEBIT ÷ Revenue | -91.3% | +26.7% | +23.4% | +25.7% |
| Net MarginNet income ÷ Revenue | -60.8% | +6.9% | +11.8% | +15.0% |
| FCF MarginFCF ÷ Revenue | -57.6% | +30.6% | +15.0% | +24.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -77.8% | +10.0% | +5.4% | +2.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.7% | +57.4% | -9.5% | +9.2% |
ABBV leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
BMY leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 16.3x trailing earnings, BMY trades at a 81% valuation discount to ABBV's 85.5x P/E. On an enterprise value basis, BMY's 9.2x EV/EBITDA is more attractive than ABBV's 15.0x.
| Metric | ROIVRoivant Sciences … | ABBVAbbVie Inc. | PFEPfizer Inc. | BMYBristol-Myers Squ… |
|---|---|---|---|---|
| Market CapShares × price | $20.5B | $358.4B | $150.6B | $114.8B |
| Enterprise ValueMkt cap + debt − cash | $17.9B | $422.3B | $216.9B | $151.8B |
| Trailing P/EPrice ÷ TTM EPS | -117.83x | 85.50x | 19.47x | 16.30x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 14.28x | 8.94x | 8.93x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 14.96x | 10.66x | 9.17x |
| Price / SalesMarket cap ÷ Revenue | 706.10x | 5.86x | 2.41x | 2.38x |
| Price / BookPrice ÷ Book value/share | 3.95x | — | 1.74x | 6.20x |
| Price / FCFMarket cap ÷ FCF | — | 20.12x | 16.60x | 8.94x |
BMY leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
Evenly matched — ROIV and ABBV and BMY each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
ABBV delivers a 62.1% return on equity — every $100 of shareholder capital generates $62 in annual profit, vs $-16 for ROIV. ROIV carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to BMY's 2.55x. On the Piotroski fundamental quality scale (0–9), BMY scores 8/9 vs ROIV's 5/9, reflecting strong financial health.
| Metric | ROIVRoivant Sciences … | ABBVAbbVie Inc. | PFEPfizer Inc. | BMYBristol-Myers Squ… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -16.3% | +62.1% | +8.3% | +39.0% |
| ROA (TTM)Return on assets | -15.5% | +3.1% | +3.6% | +7.9% |
| ROICReturn on invested capital | -50.4% | +23.9% | +7.5% | +16.9% |
| ROCEReturn on capital employed | -16.4% | +21.5% | +9.0% | +18.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 7 | 8 |
| Debt / EquityFinancial leverage | 0.02x | — | 0.78x | 2.55x |
| Net DebtTotal debt minus cash | -$2.6B | $63.8B | $66.3B | $36.9B |
| Cash & Equiv.Liquid assets | $2.7B | $5.2B | $1.1B | $10.2B |
| Total DebtShort + long-term debt | $100M | $69.1B | $67.4B | $47.1B |
| Interest CoverageEBIT ÷ Interest expense | — | 3.28x | 4.02x | 10.33x |
Evenly matched — ROIV and ABBV and BMY each lead in 3 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ROIV leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ROIV five years ago would be worth $28,537 today (with dividends reinvested), compared to $8,674 for PFE. Over the past 12 months, ROIV leads with a +153.2% total return vs ABBV's +11.3%. The 3-year compound annual growth rate (CAGR) favors ROIV at 46.7% vs PFE's -6.6% — a key indicator of consistent wealth creation.
| Metric | ROIVRoivant Sciences … | ABBVAbbVie Inc. | PFEPfizer Inc. | BMYBristol-Myers Squ… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +29.0% | -10.1% | +6.9% | +7.6% |
| 1-Year ReturnPast 12 months | +153.2% | +11.3% | +23.7% | +23.4% |
| 3-Year ReturnCumulative with dividends | +215.6% | +50.4% | -18.4% | -7.1% |
| 5-Year ReturnCumulative with dividends | +185.4% | +101.3% | -13.3% | +5.2% |
| 10-Year ReturnCumulative with dividends | +171.9% | +295.5% | +29.6% | +6.7% |
| CAGR (3Y)Annualised 3-year return | +46.7% | +14.6% | -6.6% | -2.4% |
ROIV leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ROIV and ABBV each lead in 1 of 2 comparable metrics.
Risk & Volatility
ABBV is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than ROIV's 0.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ROIV currently trades 93.2% from its 52-week high vs ABBV's 82.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ROIVRoivant Sciences … | ABBVAbbVie Inc. | PFEPfizer Inc. | BMYBristol-Myers Squ… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 0.34x | 0.54x | 0.50x |
| 52-Week HighHighest price in past year | $30.33 | $244.81 | $28.75 | $62.89 |
| 52-Week LowLowest price in past year | $10.58 | $176.57 | $21.97 | $42.52 |
| % of 52W HighCurrent price vs 52-week peak | +93.2% | +82.8% | +92.1% | +89.4% |
| RSI (14)Momentum oscillator 0–100 | 54.8 | 46.8 | 44.2 | 41.4 |
| Avg Volume (50D)Average daily shares traded | 4.8M | 5.8M | 33.3M | 10.3M |
Evenly matched — ROIV and ABBV each lead in 1 of 2 comparable metrics.
Analyst Outlook
PFE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ROIV as "Buy", ABBV as "Buy", PFE as "Hold", BMY as "Hold". Consensus price targets imply 26.6% upside for ABBV (target: $257) vs 3.0% for PFE (target: $27). For income investors, PFE offers the higher dividend yield at 6.49% vs ABBV's 3.24%.
| Metric | ROIVRoivant Sciences … | ABBVAbbVie Inc. | PFEPfizer Inc. | BMYBristol-Myers Squ… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $33.20 | $256.64 | $27.27 | $62.00 |
| # AnalystsCovering analysts | 14 | 41 | 39 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | +3.2% | +6.5% | +4.4% |
| Dividend StreakConsecutive years of raises | 1 | 13 | 15 | 6 |
| Dividend / ShareAnnual DPS | — | $6.57 | $1.72 | $2.47 |
| Buyback YieldShare repurchases ÷ mkt cap | +6.3% | +0.3% | 0.0% | 0.0% |
PFE leads this category, winning 2 of 2 comparable metrics.
Key Takeaway
ABBV leads in 1 of 6 categories (Income & Cash Flow). BMY leads in 1 (Valuation Metrics). 2 tied.
Best OverallRoivant Sciences Ltd. (ROIV)Leads 1 of 6 categories
Loading custom metrics...
ROIV vs ABBV vs PFE vs BMY: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ROIV or ABBV or PFE or BMY a better buy right now?
For growth investors, AbbVie Inc.
(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -11. 2% for Roivant Sciences Ltd. (ROIV). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Roivant Sciences Ltd. (ROIV) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ROIV or ABBV or PFE or BMY?
On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.
3x versus AbbVie Inc. at 85. 5x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 8. 9x.
03Which is the better long-term investment — ROIV or ABBV or PFE or BMY?
Over the past 5 years, Roivant Sciences Ltd.
(ROIV) delivered a total return of +185. 4%, compared to -13. 3% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus BMY's +6. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ROIV or ABBV or PFE or BMY?
By beta (market sensitivity over 5 years), AbbVie Inc.
(ABBV) is the lower-risk stock at 0. 34β versus Roivant Sciences Ltd. 's 0. 95β — meaning ROIV is approximately 182% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Roivant Sciences Ltd. (ROIV) carries a lower debt/equity ratio of 2% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.
05Which is growing faster — ROIV or ABBV or PFE or BMY?
By revenue growth (latest reported year), AbbVie Inc.
(ABBV) is pulling ahead at 8. 6% versus -11. 2% for Roivant Sciences Ltd. (ROIV). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -104. 6% for Roivant Sciences Ltd.. Over a 3-year CAGR, ABBV leads at 1. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ROIV or ABBV or PFE or BMY?
Bristol-Myers Squibb Company (BMY) is the more profitable company, earning 14.
6% net margin versus -592. 0% for Roivant Sciences Ltd. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -34. 5% for ROIV. At the gross margin level — before operating expenses — ROIV leads at 96. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ROIV or ABBV or PFE or BMY more undervalued right now?
On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 8.
9x forward P/E versus 14. 3x for AbbVie Inc. — 5. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABBV: 26. 6% to $256. 64.
08Which pays a better dividend — ROIV or ABBV or PFE or BMY?
In this comparison, PFE (6.
5% yield), BMY (4. 4% yield), ABBV (3. 2% yield) pay a dividend. ROIV does not pay a meaningful dividend and should not be held primarily for income.
09Is ROIV or ABBV or PFE or BMY better for a retirement portfolio?
For long-horizon retirement investors, AbbVie Inc.
(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, ROIV: +171. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ROIV and ABBV and PFE and BMY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ROIV is a mid-cap quality compounder stock; ABBV is a large-cap income-oriented stock; PFE is a mid-cap income-oriented stock; BMY is a mid-cap deep-value stock. ABBV, PFE, BMY pay a dividend while ROIV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ROIV: -77.8% · ABBV: 10.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.